Key facts
- This page summarizes Julianne Bruno's Form 4 filing for CRISPR Therapeutics AG (CRSP).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2025, 17:35.
Julianne Bruno - 14 Mar 2025 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- CRSP
- Reported as of
- 14 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Mar 2025, 17:35:05 UTC
- Prior SEC filing
- 12 Mar 2025
- Next SEC filing
- 24 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- Elizabeth Ryland Waldinger, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Julianne Bruno filed Form 4 for CRISPR Therapeutics AG (CRSP) on 18 Mar 2025.
Change
- Previous filing in this sequence was filed on 12 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRSP
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +36,666
- Change %
- Price
- $0.000000
- Shares after
- 36,666
- Date
- 14 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 36,666
- Exercise price
- $42.12
- Footnotes
- F1
CRSP
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +27,500
- Change %
- Price
- $0.000000
- Shares after
- 27,500
- Date
- 14 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 27,500
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option was granted on March 14, 2025 with respect to 36,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 14, 2025.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
Footnote F3
This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.